Research News & Publications

Exhaustion affects CAR T–cell clinical response

11/30/2021

Clinical trial data reveals what controls the staying power of T cells, affecting immunotherapy responses. St. Jude scientists' findings were published in Cell Reports.
Discovery of how immune cells sense nutrients offers new therapeutic insight

11/18/2021

St. Jude scientists map nutrient-dependent signaling in T cells, offering possible new drug targets for treating infectious diseases, cancer and immune-mediated disorders.
Target prevents T-cell exhaustion, boosts CAR T–cell responses

11/17/2021

Findings from St. Jude Children’s Research Hospital show how epigenetic regulation by the enzyme DNMT3A controls T-cell exhaustion providing a target for improving CAR T–cell immunotherapy.
St. Jude researchers are again among the world’s most highly cited scientists

11/16/2021

The fourteen scientists are among the most highly cited investigators in the world during the past decade, reflecting the international reach of St. Jude research.
Safety concerns raised for neuroblastoma candidate drug

11/09/2021

St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.
Together by St. Jude Teaches Children about the COVID-19 Vaccines in New Coloring Book

11/02/2021

Following FDA authorization of the COVID-19 vaccine for children ages 5 to 11, St. Jude releases a free coloring book that educates children on vaccines.
Cell-free DNA identifies early signs of relapse in pediatric medulloblastoma

10/21/2021

Findings from St. Jude Children’s Research Hospital show that cell-free DNA in cerebrospinal fluid can be used to detect measurable residual disease and identify patients at risk of relapse.
Biomarker predicts medulloblastoma relapse

10/21/2021

St. Jude scientists developed a test to look for signals that identify the presence of cell-free DNA from medulloblastoma.
Changing tumor cell identity

10/20/2021

Scientists at St. Jude and Dana-Farber Cancer Institute learned how retinoic acid changes tumor cells in children with high-risk neuroblastoma.
Promising preclinical cancer therapy harnesses a newly discovered cell death pathway

10/19/2021

Results offer clues for enhancing interferon effectiveness in cancer treatment.